CDER chal­lenges On­copep­tides’ ap­peal over Pepax­to with­draw­al

FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search is ob­ject­ing to On­copep­tides’ ap­peal of the agency’s re­quest to with­draw its can­cer drug Pepax­to.

Pepax­to was first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER